



(51) International Patent Classification:

C12N 9/48 (2006.01) A61K 38/48 (2006.01)

C12N 15/62 (2006.01) A61P 31/14 (2006.01)

(21) International Application Number:

PCT/SG2022/050775

(22) International Filing Date:

27 October 2022 (27.10.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

10202112143T 01 November 2021 (01.11.2021) SG

(71) Applicant: **AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH** [SG/SG]; 1 Fusionopolis Way, #20-10 Connexis North Tower, Singapore 138632 (SG).(72) Inventors: **WANG, Cheng-I**; c/o Singapore Immunology Network, 8A Biomedical Grove, #03-06, Singapore 138648 (SG). **LEE, Chia Yin**; c/o Singapore Immunology Network, 8A Biomedical Grove, #03-06, Singapore 138648(SG). **MINHAT, Rabiatul Adawiyah Binte**; c/o Singapore Immunology Network, 8A Biomedical Grove, #03-06, Singapore 138648 (SG). **WANG, Bei**; c/o Singapore Immunology Network, 8A Biomedical Grove, #03-06, Singapore 138648 (SG). **HUBER, Roland**; c/o A*STAR Bioinformatics Institute, Matrix #07-01, 30 Biopolis Street, Singapore 138671 (SG). **DEFALCO, Louis**; c/o A*STAR Bioinformatics Institute, Matrix #07-01, 30 Biopolis Street, Singapore 138671 (SG). **HUANG, Ching-Wen**; c/o Singapore Immunology Network, 8A Biomedical Grove, #03-06, Singapore 138648 (SG).(74) Agent: **DONALDSON & BURKINSHAW LLP**; 24 Raffles Place, #15-00 Clifford Centre, Singapore 048621 (SG).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,

(54) Title: RECOMBINANT/FUSION POLYPEPTIDES COMPRISING MUTATED ANGIOTENSIN CONVERTING ENZYME 2 (ACE2)

Higher affinity ACE2 by computational prediction




Fig. 1A

(57) Abstract: The invention relates to recombinant mutated angiotensin converting enzyme 2 (ACE2) comprising one or more amino acid substitutions at amino acid positions T27, F28, K31, H34, Y41 and Q42 which have improved binding affinity to SARS-CoV-1 and/or SARS-CoV-2. It also relates to combinatorial mutant ACE2 comprising T27Y/K31 H/H34A, T27YZ K31 H/H34V and T27Y/K31 Y/H34V and the use of said mutant ACE2 for treating and preventing coronavirus infection.

[Continued on next page]

NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:

15 June 2023 (15.06.2023)